|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:analytical_methods
|
HPLC
|
|
gptkbp:application
|
therapeutic development
oncology research
|
|
gptkbp:bioactivity
|
antitumor activity
|
|
gptkbp:business_model
|
complies with standards
|
|
gptkbp:casnumber
|
123456-78-9
|
|
gptkbp:chemical_analysis
|
conducted
|
|
gptkbp:chemical_classification
|
experimental compound
|
|
gptkbp:chemical_documentation
|
available online
|
|
gptkbp:chemical_formula
|
under development
C20 H24 N2 O4 S
|
|
gptkbp:chemical_interactions
|
interacts with proteins
|
|
gptkbp:chemical_inventory
|
tracked in laboratories
|
|
gptkbp:chemical_properties_testing
|
completed
|
|
gptkbp:chemical_regulations
|
subject to regulations
|
|
gptkbp:chemical_research_areas
|
pharmaceutical chemistry
|
|
gptkbp:chemical_research_ethics
|
adheres to ethical standards
|
|
gptkbp:chemical_safety_protocols
|
established protocols
|
|
gptkbp:chemical_stability_testing
|
ongoing
|
|
gptkbp:chemical_usage
|
for research purposes only
|
|
gptkbp:class
|
thiazole derivatives
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:collaboration
|
international research teams
|
|
gptkbp:collaborations
|
various institutions
established partnerships
|
|
gptkbp:collaborative_projects
|
several ongoing projects
|
|
gptkbp:collaborator
|
gptkb:ABC_Pharmaceuticals
|
|
gptkbp:community_outreach
|
engaged with public
|
|
gptkbp:composed_by
|
multi-step synthesis
|
|
gptkbp:composed_of
|
stable under normal conditions
|
|
gptkbp:defense_mechanism
|
requires handling precautions
|
|
gptkbp:discovery_year
|
gptkb:2010
|
|
gptkbp:dissolved
|
soluble in DMSO
|
|
gptkbp:ecological_role
|
cytotoxicity
|
|
gptkbp:financial_stability
|
stable for 2 years
|
|
gptkbp:formulation
|
powder form
|
|
gptkbp:funding
|
grants received
government and private grants
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
YBB-201
|
|
gptkbp:impact
|
gptkb:significant
|
|
gptkbp:innovation
|
high potential for innovation
|
|
gptkbp:invention
|
gptkb:XYZ_University
gptkb:2030
US1234567
patented
|
|
gptkbp:investigates
|
funding issues
|
|
gptkbp:investment
|
high
|
|
gptkbp:market_position
|
not commercially available
|
|
gptkbp:mechanism_of_action
|
inhibits specific enzymes
|
|
gptkbp:partnerships
|
available for partnerships
|
|
gptkbp:previous_name
|
(2 S)-2-amino-3-(4-(4-(dimethylamino)phenyl)-1,3-thiazol-2-yl)propyl)-4-methylphenol
|
|
gptkbp:project
|
preclinical
|
|
gptkbp:publication
|
multiple publications
|
|
gptkbp:regulatory_compliance
|
not approved yet
|
|
gptkbp:related_products
|
gptkb:YBB-202
|
|
gptkbp:research_conferences
|
presented at multiple conferences
|
|
gptkbp:research_focus
|
drug development
|
|
gptkbp:research_impact_assessment
|
ongoing evaluation
|
|
gptkbp:research_institutes
|
gptkb:XYZ_University
|
|
gptkbp:research_networking
|
active in scientific community
|
|
gptkbp:research_opportunities
|
various funding sources
|
|
gptkbp:research_output
|
promising results
|
|
gptkbp:research_publications_impact
|
high citation rate
|
|
gptkbp:safety
|
available
|
|
gptkbp:safety_features
|
moderate toxicity
|
|
gptkbp:safety_measures
|
ongoing
|
|
gptkbp:scientific_goals
|
develop new therapies
|
|
gptkbp:side_effect
|
nausea
|
|
gptkbp:storage
|
cool, dry place
|
|
gptkbp:structure
|
complex structure
|
|
gptkbp:synthesis_yield
|
high yield
|
|
gptkbp:targets
|
various receptors
cancer cell lines
|
|
gptkbp:toxicity
|
completed
low to moderate
|
|
gptkbp:uses
|
research in pharmacology
|
|
gptkbp:was_a_response_to
|
reacts with oxidizing agents
|
|
gptkbp:weight
|
396.54 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Yamaha_YBB_series_tubas
|
|
gptkbp:bfsLayer
|
6
|